PAIN
Volume 139, Issue 2 , Pages 479-480 , 15 October 2008

Role of placebo factors in clinical trials with special focus on enrichment designs

  • Roland Staud

      Affiliations

    • Corresponding Author InformationTel.: +1 352 273 5346; fax: +1 352 392 8483.

Received 10 July 2008 ,Accepted 28 July 2008.

References 

  1. Crofford LJ, Mease PJ, Simpson SL, Young JP, Martin SA, Haig GM, et al. Fibromyalgia relapse evaluation and efficacy for durability of meaningful relief (FREEDOM): a 6-months, double-blind, placebo-controlled trial with pregabalin. Pain. 2008;136:419–431
  2. Crofford LJ, Rowbotham MC, Mease PJ, Russell IJ, Dworkin RH, Corbin AE, et al. Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2005;52:1264–1273
  3. Price DD, Finniss DG, Benedetti F. A comprehensive review of the placebo effect: recent advances and current thought. Annu Rev Psychol. 2008;59:565–590
  4. Staud R, Price DD. Long-term trials of pregabalin and duloxetine for fibromyalgia symptoms: how study designs can affect placebo factors. Pain. 2008;136:232–234
  5. Straube S, Derry S, McQuay HJ, Moore RA. Enriched enrolment: definition and effects of enrichment and dose in trials of pregabalin and gabapentin in neuropathic pain. A systematic review. Br J Clin Pharmacol. 2008;66:266–275
  6. Vase L, Riley JL, Price DD. A comparison of placebo effects in clinical analgesic trials versus studies of placebo analgesia. Pain. 2002;99:443–452
  7. Vase L, Robinson ME, Verne GN, Price DD. The contributions of suggestion, desire, and expectation to placebo effects in irritable bowel syndrome patients – an empirical investigation. Pain. 2003;105:17–25

PII: S0304-3959(08)00424-7

doi: 10.1016/j.pain.2008.07.027

PAIN
Volume 139, Issue 2 , Pages 479-480 , 15 October 2008

Article Tools